Epoetin beta esrd use
Products billed under this code include Mircera.
Payment limit per 1 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Mircera.
Payment limit per 1 MCG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Mircera | Vifor (International) Inc. | 59353-0400-09 | 30 | $35.88 |
| Mircera | Vifor (International) Inc. | 59353-0401-09 | 50 | $59.80 |
| Mircera | Vifor (International) Inc. | 59353-0402-09 | 75 | $89.70 |
| Mircera | Vifor (International) Inc. | 59353-0403-09 | 100 | $119.60 |
| Mircera | Vifor (International) Inc. | 59353-0404-09 | 150 | $179.40 |
| Mircera | Vifor (International) Inc. | 59353-0405-09 | 200 | $239.20 |
| Mircera | Vifor (International) Inc. | 59353-0407-09 | 120 | $143.52 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.196 | +$0.106 | 1 MCG | Epoetin beta esrd use | v1, posted September 17, 2026 |
| 3Q26 | $1.09 | +$0.057 | 1 MCG | Epoetin beta esrd use | v1, posted September 15, 2026 |
| 2Q26 | $1.033 | −$0.182 | 1 MCG | Epoetin beta esrd use | v1, posted September 15, 2026 |
| 1Q26 | $1.215 | −$0.25 | 1 MCG | Epoetin beta esrd use | v1, posted September 15, 2026 |
| 4Q25 | $1.465 | +$0.051 | 1 MCG | Epoetin beta esrd use | v1, posted September 8, 2026 |
| 3Q25 | $1.414 | +$0.154 | 1 MCG | Epoetin beta esrd use | v1, posted March 10, 2026 |
| 2Q25 | $1.26 | +$0.036 | 1 MCG | Epoetin beta esrd use | v1, posted March 10, 2026 |
| 1Q25 | $1.224 | +$0.013 | 1 MCG | Epoetin beta esrd use | v1, posted December 19, 2025 |
| 4Q24 | $1.211 | +$0.136 | 1 MCG | Epoetin beta esrd use | v1, posted June 11, 2025 |
| 3Q24 | $1.075 | −$0.361 | 1 MCG | Epoetin beta esrd use | v1, posted June 11, 2025 |
| 2Q24 | $1.436 | −$0.182 | 1 MCG | Epoetin beta esrd use | v1, posted March 11, 2025 |
| 1Q24 | $1.618 | −$0.091 | 1 MCG | Epoetin beta esrd use | v1, posted December 19, 2024 |
| 4Q23 | $1.709 | +$0.062 | 1 MCG | Epoetin beta esrd use | v1, posted October 10, 2024 |
| 3Q23 | $1.647 | −$0.322 | 1 MCG | Epoetin beta esrd use | v1, posted June 5, 2024 |
| 2Q23 | $1.969 | +$0.533 | 1 MCG | Epoetin beta esrd use | v1, posted February 23, 2024 |
| 1Q23 | $1.436 | −$0.12 | 1 MCG | Epoetin beta esrd use | v1, posted December 6, 2023 |
| 4Q22 | $1.556 | −$0.065 | 1 MCG | Epoetin beta esrd use | v1, posted June 22, 2023 |
| 3Q22 | $1.621 | +$0.059 | 1 MCG | Epoetin beta esrd use | v1, posted June 9, 2023 |
| 2Q22 | $1.562 | +$0.05 | 1 MCG | Epoetin beta esrd use | v1, posted December 14, 2022 |
| 1Q22 | $1.512 | +$0.002 | 1 MCG | Epoetin beta esrd use | v1, posted June 8, 2022 |
| 4Q21 | $1.51 | −$0.021 | 1 MCG | Epoetin beta esrd use | v1, posted June 2, 2022 |
| 3Q21 | $1.531 | −$0.013 | 1 MCG | Epoetin beta esrd use | v1, posted June 2, 2022 |
| 2Q21 | $1.544 | +$0.048 | 1 MCG | Epoetin beta esrd use | v1, posted March 1, 2022 |
| 1Q21 | $1.496 | – | 1 MCG | Epoetin beta esrd use | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.